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First discovered as an oncogene in leukaemia, recent reports highlight an emerging role for the 
proto-oncogene BCL-3 in solid tumours. Importantly, BCL-3 is highly expressed in >30% of 
colorectal cancers and reported to be associated with poor prognosis. However, the mechanism 
by which BCL-3 regulates tumorigenesis in the large bowel is yet to be fully elucidated. Here 
we show for the first time that depleting BCL-3 can suppress cyclooxygenase-2 (COX-
2)/Prostaglandin E2 (PGE2) signalling in colorectal cancer cells, a pathway known to drive 
many of the hallmarks of cancer. 
RNAi-mediated suppression of BCL-3 expression decreased COX-2 expression in colorectal 
cancer cells both at the mRNA and protein level. This reduction in COX-2 expression led to a 
significant and functional reduction (30-50%) in the amount of pro-tumorigenic PGE2 
produced by the cancer cells, as shown by enzyme linked immunoassay and medium exchange 
experiments. In addition, inhibition of BCL-3 expression also significantly suppressed 
cytokine-induced (TNF-α or IL-1β) COX-2 expression. Taken together, this report identifies a 
novel role for BCL-3 in colorectal cancer and suggests that expression of BCL-3 may be a key 
determinant in the COX-2 response to inflammatory cytokines in colorectal tumour cells. 
We propose that targeting BCL-3 to suppress PGE2 synthesis may represent an alternative or 








Colorectal cancer (CRC) is a major cause of cancer related mortality and is the third most 
common cause of cancer death in the UK (1, 2). CRC is a multifactorial disease, with both 
genetic predisposition and environmental factors playing a critical role in its development. 
Environmental factors that promote colorectal tumorigenesis include chronic inflammation; 
there are a number of important regulatory pathways linking inflammation and colorectal 
cancer, such as chemokines, cytokines, NF-κB, cyclooxygenase-2 (COX-2) and its metabolic 
product prostaglandin E2 (PGE2) (3, 4). Deregulation of the COX-2/PGE2 pathway is 
considered to be an important, relatively early event in colorectal tumorigenesis, not only 
because of its role in shaping the tumour microenvironment, but also for enabling many of the 
hallmarks of cancer (5). 
Despite a focus on NF-κB canonical signalling in carcinogenesis (6-9), the NF-κB homodimer 
subunits NF‐κB1 (p50/p50) and NF‐κB2 (p52/p52) have become the subject of intense interest 
as they represent an alternative mode of NF-κB activation (the atypical NF-κB pathway; 
reviewed in (10)). Although they function as transcriptional repressors due to their lack of 
transactivation domains (TAD), they can bind transcriptional co-activators via their C-terminal 
ankyrin repeats (involved in protein-protein interactions) and therefore play a direct role in 
positively or negatively regulating NF‐κB target genes (11). First identified in subgroup of B-
cell chronic lymphocytic leukaemias (12, 13), BCL-3 selectively binds to the NF-κB 
homodimers and depending on the nature of the stimuli can function as either a co-activator or 
as an inhibitor of NF-κB (14-17). 
BCL-3 has been found to be widely expressed in solid tumours (18); in particular, elevated 
levels of BCL-3 and p52 homodimers have been linked to immortalized human breast epithelial 





metastatic breast cancer (20). Furthermore, it has been shown that BCL-3 can promote 
colorectal tumorigenesis by increasing colorectal cancer cell survival through AKT activation 
(21), through stabilizing c-MYC protein via ERK activation and by promoting the cancer stem 
cell phenotype by enhancing β-catenin signalling (22, 23).  
Importantly, BCL‐3 expression is reported to be de-regulated in colorectal cancer tissue (24); 
high BCL-3 protein expression associated with poor prognosis in colorectal cancer patients 
(22).  Cytoplasmic localisation of BCL-3 has also been suggested as a potential early diagnostic 
marker in colorectal cancer (25). Furthermore, BCL-3 expression is up-regulated by key 
cytokines including tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (18, 26, 27), 
potentially representing a novel mechanism linking inflammation and cancer.  
Given the importance of COX-2/PGE2 signalling in colorectal tumorigenesis, it is perhaps 
surprising that the impact of BCL-3 on the expression of COX-2/PGE2 signalling in colorectal 
cancer has not been investigated before.  In this study we show that depleting BCL-3 expression 
can inhibit the COX-2/PGE2 pathway and that BCL-3 could be a key determinant in the COX-
2 response to inflammatory cytokines in colorectal tumour. We suggest that targeting BCL-3 
to suppress PGE2 synthesis may be important in preventing early tumour development and 
tumour recurrence, making BCL-3 an attractive target for cancer prevention either as an 
alternative or as a complementary approach to using conventional COX inhibitors (non-






Materials and Methods 
Cell line and cell culture conditions 
The human colorectal adenocarcinoma-derived cell line HCA7 was a kind gift from Dr Susan 
Kirkland, (Imperial College, London UK); cells were mycoplasma tested on receipt (Mycoalert 
Plus mycoplasma detection kit, Lonza, Basal, Switzerland). The human colorectal 
adenocarcinoma-derived cell line HT-29 and human rectal adenocarcinoma-derived cell line 
SW837 were obtained from the American Type Culture Collection (ATCC, MD, USA, Cat. 
No. HTB-38 and CCL-235 respectively) and mycoplasma tested on receipt. All experiments 
were carried out within 6 passages and cells were routinely characterised (see below). The 
human colorectal adenocarcinoma-derived HCT116, HCT15, SW480, SW620, LOVO, 
LS174T and specifically rectal SW1463 cell lines were obtained from the American Type 
Culture Collection (ATCC, MD, USA, Cat. No. CCL-247, CCL-225, CCL-228, CCL-227, 
CCL-229, CL-118 and CCL-234 respectively), cells were mycoplasma tested on receipt and 
experiments carried out within 6 passage of receiving. All cell lines were maintained as 
previously described (28). Cell lines were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Gibco, Thermo Fisher Scientific, UK), supplemented with 10% fetal bovine serum 
(FBS), 2mM glutamine (Gibco, Thermo Fisher Scientific, UK), 100U/ml penicillin and 
100μg/ml streptomycin (Gibco, Thermo Fisher Scientific, UK). The human colorectal 
adenoma- PC/AA/C1, S/AN/C1, S/RG/C2 and transformed adenoma- PC/AA/C1/SB10 cell 
lines were derived in this laboratory and grown as described previously (29, 30). Growth 
medium was DMEM supplemented with 20% FBS, 1µg/ml hydrocortisone sodium succinate, 
0.2 units/ml insulin, 2mM glutamine, 100U/ml penicillin and 100μg/ml streptomycin. 24h 
conditioned medium (CM) was harvested from BCL-3 siRNA, COX-2 siRNA or negative 
control transfected HCA7 cells, filtered and used to culture S/RG/C2 adenoma for 72h (CM 





PGE2 (Sigma-Aldrich, Gillingham, UK) to the CM prior to culture. All cell lines were routinely 
checked for microbial contamination (including mycoplasma) and molecularly characterised 
using an “in house” panel of cellular and molecular markers to check that cell lines have not 
been cross contaminated (every 3-6 month). Stocks were securely catalogued and stored; 
passage numbers strictly adhered to preventing phenotypic drift.  
Determining percentage of floating cells as a measure of apoptosis. 
Growth medium from individual flasks was collected and the floating cells counted. Attached 
cell yield was determined by trypanising and counting the number of viable cells from the same 
flask. The floating cells are represented as a proportion of the total cell population (floating 
and attached), accepted as a measure of cell death (31). 
RNA interference 
Cells were reverse transfected using Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher, 
UK), as per manufacturer’s instructions, with small interfering RNAs (siRNAs final 
concentration 50nM) from Dharmacon (Horizon Discovery, Cambridge, UK) targeting BCL-
3 (individual sequences) or COX-2 (pooled siRNAs) (21). Cells were incubated overnight at 
37°C, before being medium changed onto fresh growth medium.  
Reverse Transcription (RT) 
Total RNA was extracted from cells using Tri-Reagent (Sigma-Aldrich, Gillingham, UK), a 
RNeasy mini kit (Qiagen, Manchester, UK) was utilised according to manufacturer’s 
instructions with an additional on-column DNase digestion (RNase-Free DNase Set; Qiagen, 
Manchester, UK), prior to cDNA synthesis. The RNA concentration of the sample was 
measured using a NanoDrop (Thermo Scientific, Karlsruhe, Germany).  
Complementary DNA (cDNA) was synthesised from 2µg of RNA by reverse transcription 





reverse transcriptase, (Promega, Southampton, UK). A second tube, in the absence of the 
reverse transcriptase was synthesised as a negative control, no RT. The samples were diluted 
further giving a final concentration of 10ng/µL.  
Real-Time Quantitative-PCR (RT-qPCR)  
Having achieved optimisation of primers and ensured the annealing temperature gave a near 
100% efficient amplification per cycle, RT-qPCR was performed as previously described (22), 
using SYBR Green PCR Mix (Qiagen, Manchester, UK) and the following Qiagen QuantiTect 
primers (Manchester, UK), at a dilution of 1:10: BCL-3 (QT00040040), COX-2 
(QT00040586); with gene expression normalised to housekeeping gene TBP (QT00000721) or 
HPRT (QT00059066). The QuantiTect primer assays sets are designed to have annealing 
temperatures of 55°C, a 40-cycle program was performed on a MxPro 3005P Real-time 
Thermal Cycler (Agilent Technologies, West Lothian, UK); samples carried out in triplicate 
with one no RT well per condition. Amplification data was analysed using MxPro software 
(Stratagene, Stockport, UK), by means of the ΔΔCq method (32). 
Immunoblotting 
Whole-cell lysates were prepared in situ, on ice, using 100µl 1x lysis buffer (Cell Signaling 
Technology, Danvers, MA, USA) with the addition of a Protease Inhibitor Cocktail Tablet 
(Roche, Basal, Switzerland) per 10ml of lysis buffer. The cell debris was removed by 
centrifugation for 10 minutes at 18,500g. Protein concentration of the cell lysate was 
determined using the Bio-Rad DC Protein Assay Kit (Bio-Rad, Hemel Hempstead, UK), as per 
manufacturer’s instructions. Absorption was measured in duplicate at 750nm using an iMark 
Microplate Absorbance Reader (Bio-Rad, Hemel Hempstead, UK). Samples of 100µg total 





water. 5µl of 5x Laemmli buffer was added to each lysate sample and boiled together for 5 
minutes. 
Mini-Protean 3 Electrophoresis Cells (Bio-Rad, Hemel Hempstead, UK) were used to cast 9% 
acrylamide resolving gels, using 1.5mm spacers. Gels were run at 100V for approximately 15 
minutes permitting the samples to move through the stack, before voltage was increase to 180V 
for approximately an hour or until the blue dye front had migrated through the gel. Following 
separation of the protein samples using SDS-PAGE the proteins were transferred onto 
Immobilon-P, a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, MA, 
USA). The gel and membrane were then assembled into a Transblot Cell (Bio-Rad, Hemel 
Hempstead, UK), a voltage of 100V was applied for 1.5 hours. The membrane was blocked in 
5% (w/v) milk blocking buffer for a minimum of 1 hour before being subjected to 
immunoblotting. as previously described (33), using antibodies diluted in 0.5% (w/v) milk 
dilution buffer: rabbit polyclonal anti-BCL-3 (23959-1-AP, Proteintech, UK), goat polyclonal 
anti-COX-1 (sc-1752; Santa Cruz Biotechnology, CA, USA), goat polyclonal anti-COX-2 (sc-
1745; Santa Cruz Biotechnology, CA, USA) or rabbit polyclonal anti-15-PGDH (ab37148; 
Abcam, Cambridge, UK). The membranes were incubated overnight at 4°C, after which they 
were given three 10 minute washes in Tris-Buffered Saline - 0.1% (v/v) Tween 20 (TBS-T); 
following incubation with an appropriate horseradish peroxidise- (HRP-) conjugated secondary 
antibody diluted in 0.5% (w/v) milk dilution buffer. After an hour incubation at room 
temperature with rotation, three further 10-minute washes in TBS-T were completed and the 
membrane rinsed in distilled water prior to detection by chemiluminescence (LumiGLO 
Peroxidase Chemiluminescence Substrate, KPL, Gaithersburg, MD, USA). The signal was 
detected by film developed in a Compact X4 Film Processor (XOgraph Imaging Systems Ltd., 





(between 1-20 minutes). Equal loading was confirmed with monoclonal mouse anti--tubulin 
(T9026; Sigma, Gillingham, UK). 
Blots were quantified using Image J software (NIH, Maryland, USA), this densitometry tool 
was used to measure the change in intensity of individual western blot bands. 
PGE2 Assay 
PGE2 released by cells into culture media was quantified, using a PGE2 enzyme immunoassay 
solid well kit (Cayman Chemical Europe, Estonia), that uses a high-affinity PGE2 monoclonal 
antibody for quantification of PGE2. Medium collected from 70% confluent HCA7 cells was 
snap frozen in liquid nitrogen (−196°C) and stored at −70°C. PGE2 levels were determined 
using the immunoassay kit, as described previously (34). Cells were pre-treated with TNF-α 
(100ng/ml, Insight Biotechnology Ltd., UK) for 16h or NS-398 (20μM/ml, Sigma-Aldrich, 
Gillingham, UK) for 24 hours as required. Samples were performed in triplicate. 
Statistical analysis 
Statistical analysis, ANOVA, student and one sample t-tests, were performed using GraphPad 
Prism (GraphPad Software Inc, California, USA), and represented as *p≤0.05; **p≤0.01; 
***p≤0.001; NS=non-significant.  Results are expressed as mean values ± standard error of the 
mean (SEM) where a minimum of three independent experiments were performed. Where a 
single experiment was performed the mean of triplicate readings ± standard deviation (SD).  
 
Results 
Suppression of BCL-3 expression decreases COX-2 expression in colorectal cancer cells. 
This study was based on the observation that suppression of BCL-3 consistently repressed 
PTGS2 expression in a number of human colorectal cancer cell lines (data from focused mini 





2/PGE2 signalling in colorectal cancer. For these studies HCA7 human colorectal cancer cells 
(high endogenous COX-2 expression, high BCL-3 expression (Figure 1A) were transfected 
with BCL-3 siRNA and the expression of COX-2 was determined (Figure 1B). Cells were 
transfected with 50nM BCL-3 siRNA or non-targeting control. To confirm the specificity of 
the siRNA and to control for off-target effects, BCL-3 expression was silenced using four 
separate siRNA sequences (A, B, C and D). Importantly, transfection with the all four separate 
siRNA sequences led to a reduction in the level of COX-2 protein (Figure 1B). The expression 
of both BCL-3 and COX-2 proteins in HCA7 cells was assessed at 24, 48 and 72h post-
transfection (Figure 1C). Western blot analysis showed that the level of COX-2 protein was 
reduced following suppression of BCL-3 at all-time points (Figure 1C(i)). BCL-3 and COX-2 
mRNA was evaluated by RT-qPCR. Results are presented as fold change of the negative 
siRNA transfected levels (Figure 1C(ii)). Suppression of BCL-3 expression resulted in a greater 
than 60% reduction in COX-2 mRNA, confirming that down-regulation of BCL-3 in colorectal 
cancer cells decreases both the COX-2 mRNA and protein expression. 
To determine whether BCL-3 could regulate COX-2 expression in other colorectal cancer cell 
lines, HT-29 (which has an intermediate level of endogenous COX-2 protein expression, Figure 
1D) and the SW837 rectal cancer cell line (low endogenous COX-2 protein expression, Figure 
1E) were investigated, Transfection with BCL-3 siRNA also led to suppression of COX-2 
mRNA and protein in both cell lines. 
Suppression of BCL-3 expression decreases COX-2/PGE2 signalling. 
To confirm that the decrease in COX-2 expression on transfection with BCL-3 siRNA resulted 
in reduced COX-2 activity, PGE2 levels were measured in the culture medium. (PGE2 is a 
cyclooxygenase derived metabolite of arachidonic acid (5).) HCA7 cells were selected for this 





enzyme linked immunoassay (EIA) (Figure 2A). COX-1 and 15-PGDH protein expression 
were also assessed by western blotting 72h after BCL-3 siRNA transfection (Figure 2B); to 
ensure that other enzymes which control PGE2 levels were not also regulated.  Furthermore, 
cells were treated with NS-398 (20μM; a dose selective for COX-2 inhibition (35)) to further 
validate that changes in PGE2 detected in the cell culture medium were due to COX-2 and not 
COX-1 activity (Figure 2A). The results show that there was significant inhibition (p-
value=0.048) of PGE2 production when BCL-3 expression is suppressed; there was an 
approximate 30% decrease in basal PGE2 production on BCL-3 siRNA transfection when 
compared to the negative siRNA control. Importantly, the production of more than 90% of the 
PGE2 was blocked by the COX-2 selective inhibitor NS-398 (Figure 2A). Finally, COX-1 and 
15-PGDH levels were not regulated on transfection with the BCL-3 siRNA (Figure 2B). Taken 
together, these findings show that the observed decrease in PGE2 production in the BCL-3 
siRNA transfected cells is due to a loss of COX-2 activity.  
We next wanted to investigate whether the regulation of PGE2 observed by suppression of 
BCL-3 could affect the survival of other tumour cells. For this we carried out conditioned 
medium exchange experiments, using a PGE2 sensitive adenoma derived cell line (S/RG/C2). 
Previous studies have shown that PGE2 promotes the growth of S/RG/C2 (36). Conditioned 
medium (CM) from the BCL-3 siRNA, COX-2 siRNA or negative control transfected HCA7 
cells was harvested and used to culture the S/RG/C2 adenoma derived cell line (refer to 
methods). It is important to note the number of HCA7 cells is not affected by BCL-3 or COX-
2 suppression during the preparation of conditioned medium (over the 72h period, 
Supplementary Figure 1A); results are summarised in Figure 2C. Treating S/RG/C2 cells with 
CM from the BCL-3 siRNA transfected HCA7 cells resulted in a significant increase (p=0.015) 
floating cells which is a measure of cell death (31). Importantly, this cell death could be rescued 





culture. In addition, the cell death was similar to that seen in cells grown in CM from HCA7 
transfected with the COX-2 siRNA (Figure 2C). These findings suggest that the changes in 
PGE2 secretion caused by silencing BCL-3 can affect the survival of PGE2 sensitive tumour 
cells. 
In summary, experiments show that inhibition of BCL-3 expression suppresses COX-2 and 
significantly reduces the amount of potentially pro-tumorigenic PGE2 produced by the cancer 
cells.  
Induction of COX-2 expression by TNF-α or IL-1β can be partially blocked by 
suppressing BCL-3 expression in colorectal cancer cells. 
COX-2 protein has been identified as an immediate-early response gene that although normally 
absent from most cells, may be induced at sites of inflammation in response to cytokines such 
as TNF-α and IL-1β (37). These cytokines have also been shown to increase COX-2 expression 
in colorectal cancer cells (3, 38, 39). To address whether targeting BCL-3 could reduce the 
induction of COX-2 in response to inflammatory cytokines, HCA7 and HT-29 cells were 
treated with 100ng/ml of TNF-α for up to 72h (Figure 3) whilst SW837 were treated with 
10ng/ml IL-1β (Figure 4; SW837 are less responsive to TNF-α). BCL-3 and COX-2 protein 
expression were measured over 72h, the concentration of TNF-α and IL-1β used had been 
previously optimized (40). The first thing to note is that BCL-3 protein levels increase after 2h 
with exposure to TNF-α (Figure 3A) reaching a peak at 4h-8h treatment and returning to basal 
levels by 72h. COX-2 expression followed BCL-3 induction; COX-2 is induced at 4h-8h, and 
remained high for 24h-48h treatment with TNF-α, consistent with it being regulated by BCL-
3 (Figure 3A). Notably, the increased expression of COX-2 in response to TNF-α treatment 
(shown in Figure 3B at 4h) was found to be partially blocked following the suppression of 
BCL-3 in both HCA7 and HT-29 cell lines. Importantly, suppression of BCL-3 also inhibited 





findings were observed in the SW837 cells treated with 10ng/ml IL-1β (Figure 4A-D). Due to 
the low protein expression in the SW837 cells, expression of both BCL-3 and COX-2 were 
also measured using RT-qPCR (Figure 4B and D). Again, there is rapid induction of BCL-3 
(within 2h) after IL-1β treatment, followed by a more prolonged induction of COX-2 (Figures 
4A[protein], 4B[mRNA]). In addition, the increase in COX-2 expression 2h-4h after IL-1β 
treatment was partially blocked following suppression of BCL-3 by siRNA (Figure 
4C[protein], 4D[mRNA]). This data shows that inhibition of BCL-3 expression not only 
reduced basal COX-2 but also significantly supresses cytokine induced COX-2 expression. 
These results suggest that expression of BCL-3 may be an important determinant in the COX-
2 response to inflammatory cytokines.  
 
Discussion: 
Discovered as an oncogene in leukaemia, BCL-3 has been found to be overexpressed in a range 
of solid tumours including breast (19), prostate (41), endometrial (42) and nasopharyngeal  
(43). The importance of BCL-3 in colorectal carcinogenesis is supported by both clinical and 
mechanistic studies. Puvvada and colleagues were the first to show that high nuclear BCL-3 
correlated with poor prognosis in colorectal cancer patients (24), and Saamarthy et al. propose 
BCL-3 cellular localisation as a marker for early diagnosis in colorectal cancer (25). Both 
studies report that at least 30% of colorectal tumours had increased nuclear expression of BCL-
3 (24, 25). More recently high BCL-3 expression has been associated with worse survival in 
CRC (22) 
Importantly, there are a number of studies that begin to shed light on the mechanism(s) by 
which BCL-3 can promote colorectal carcinogenesis; we have shown that BCL-3 expression 
promotes AKT mediated cell survival and drives colorectal tumour growth in vivo (21), BCL-





BCL-3 has been implicated in promoting tumorigenesis through inhibition of DNA damage 
induced p53 activation by up-regulating MDM2 expression (44), and to induce cyclin D and 
cell cycle progression (45). Most recently, we have shown that BCL-3 promotes the cancer 
stem cell phenotype by enhancing β-catenin signalling in colorectal tumour cells  (reviewed in 
(46)). 
Given the importance of increased COX-2 in colorectal tumorigenesis, our novel finding that 
BCL-3 regulates PTGS2 gene expression and COX-2/PGE2 signalling identifies a new 
mechanism to support the oncogenic actions of BCL-3 in colorectal cancer. Although not 
required for COX-2 expression, we propose that nuclear BCL-3 acts as a transcriptional co-
factor (as recently proposed for β-catenin-dependent gene targets for example, (22)). It remains 
to be determined whether BCL-3 enhances NF-κB-dependent COX-2 regulation or acts via 
recruiting other co-regulators, such as Pirin, Tip60, Jab1 and Bard1 (47). The ability of BCL-
3 to regulate PGE2 production is of particular importance in light of recent studies; not only 
does PGE2 promote expression of the intestinal cancer stem cell marker LGR5 (36), but PGE2 
production by colorectal cancer cells (as well as melanoma and breast cancer cells) suppresses 
tumour immunity and fuels tumour promoting inflammation (48). COX-dependent immune 
evasion has been shown to be critical for tumour growth in colorectal cancer mouse models, 
COX-2 being reported to be responsible for the majority of circulating PGE2 (37, 48). A 
limitation of the study is that ΤΝF-α and IL-1β are only two of the upstream controllers of 
COX-2 activity, whether BCL-3 expression regulates others remains to be determined. 
Furthermore, the potential to affect many of the downstream targets of COX2/PGE2 signalling  
remains to be discovered (5). 
Here we present evidence that targeting BCL-3 expression could suppress COX-2/PGE2 





drives the hallmarks of cancer (5)), but could potentially enhance an immune response to the 
cancer. 
Taken together and given the importance of these pathways in tumour progression, targeting 
the BCL-3 protein-protein interactions (via disruption of the ankyrin repeat domain for 
example) remains a priority. It is hoped that the inhibitors of the BCL-3 pathway currently 
under development (Clarkson RWE, Cardiff University, UK) will not only suppress tumour 
cell survival and block tumour growth, but also increase anti-cancer immunity through 
suppressing COX-2/PGE2 signalling. Hence, these findings suggest BCL-3 inhibitors could be 
used as an alternative or complementary approach to using NSAIDs for prevention and/or 
recurrence in PGE2-driven tumorigenesis (49), improving the long-term prognosis for 
colorectal cancer patients.  
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Figure 1. BCL-3 knockdown reduces COX-2 expression. (A) The endogenous levels of 
BCL-3 and COX-2 in a panel of colorectal adenoma and carcinoma derived cell lines. 
Colorectal adenoma- (PC/AA/C1, S/AN/C1, S/RG/C2), transformed adenoma- 
(PC/AA/C1/SB10) and colorectal adenocarcinoma- (HT-29, HCA7, HCT116, HCT15, 
SW480, SW620, LOVO, LS174T, and specifically rectal SW837 and SW1463) derived cell 
lines were grown to approximately 70% confluence before collection of total protein for 
western blot analysis. Equal loading was confirmed by α-tubulin. (B) Western blot for BCL-3 
in HCA7 cells to validate BCL-3 siRNA sequences as well as the BCL-3 antibody. The 
expression level of BCL-3 was measured in HCA7 cells 72h after knocking down BCL-3 using 
four separate BCL-3 siRNAs sequences (A, B, C and D). The western blot is representative of 
two independent experiments. Probing for α-tubulin confirmed equal loading. Sequence A was 
used in all subsequent experiments (C-E) (i) Western blot analysis and (ii) real-time 
quantitative-PCR (RT-qPCR) mRNA analysis in (C) HCA7 (D) HT-29 and (E) SW837 cells 
transfected with 50nM of control siRNA or BCL-3 siRNA. Of note, the visible upper non-
specific band is the result of a long exposure time in order to detect low endogenous COX-2 
levels in the SW837 cells. (i) BCL-3 siRNA transfected cells were harvested for total protein 
at 24h, 48h, and 72h post-transfection and BCL-3 and COX-2 levels were assessed by western 
blot. α-tubulin was used to assess loading. The results represent three independent experiments. 
(ii) From parallel flasks, real-time quantitative PCR was carried out at 24h and 48h post-
transfection of BCL-3 siRNA, relative mRNA quantity of BCL-3 and COX-2 are presented as 
a fold change of the control negative siRNA, normalised to one. All mRNA values were 
normalised to the housekeeping gene TBP or HPRT (data represent four independent 





Figure 2. BCL-3 knockdown suppresses PGE2 production in the HCA7 cell line. (A) Data 
represents the amount of PGE2 produced (as measured by enzyme linked immunoassay, pg/ml 
per 106 cells) by HCA7 cell line and is compared to NS-398 (20μM) treated cells. Cells were 
transfected with 50nM of control siRNA or BCL-3 siRNA. PGE2 production was determined 
72h after siRNA transfection. Values are the mean of three independent experiments ±SEM, 
*P≤0.05, NS= Not Significant. (B)  Western blot shows that the down-regulation of BCL-3 has 
no effect on COX-1 or 15-PGDH protein levels up to 72h post BCL-3 siRNA transfection. 
Cells were transfected with 50nM of control siRNA or BCL-3 siRNA, and lysed on ice at 48h 
and 72h post-transfection. Results are representative of three independent experiments. (C) 
Medium exchange experiments: 24h conditioned medium (CM) was harvested from BCL-3 
siRNA, COX-2 siRNA or negative control transfected HCA7 cells and used to culture S/RG/C2 
adenoma for 72h (CM was refreshed every 24 hours). Induction of cell death is represented by 
the number of floating cells as proportion of total cell yield (31). Results are presented as a fold 
change of the control negative siRNA. 1μM PGE2 was added to CM in the rescue experiment. 
Values are the mean of three independent experiments ±SEM. ANOVA was used to determine 
the statistical significance, n=3, *P≤0.05, **P≤0.01.  
Figure 3. TNF-α induced COX-2 protein is partially blocked following the suppression of 
BCL-3 in siRNA treated cells.  (A) Western blotting shows the expression of BCL-3 and 
COX-2 proteins following TNF-α treatment (100ng/ml) in (i) HCA7 and (ii) HT-29 cells. The 
results are representative of three independent experiments. (B) Representative western blot 
shows the expression of COX-2 protein following the suppression of BCL-3 in TNF-α treated 
cells. (i) HCA7 and (ii) HT-29 cells were transfected with 50nM of control siRNA or BCL-3 
siRNA and treated with TNF-α (100ng/ml) for 4h. BCL-3 and COX-2 protein levels were 
determined at 72h post-transfection. Equal loading was confirmed by α-tubulin. Graph shows 





The quantification of COX-2 was calculated using Image J software to measure the change in 
intensity of individual western blot bands, results are presented normalized to the control. 
Results are mean values from three independent measurements ± SD. (C) Data represents the 
amount of PGE2 produced pg/ml per 10
6 cells in TNF-α (100ng/ml) treated HCA7 cells. HCA7 
cells were transfected with 50nM of control siRNA or BCL-3 siRNA. PGE2 production was 
determined 72h after siRNA transfection. Values are the means of three independent 
experiements ±SEM, *P≤0.05. 
Figure 4. IL-1β induced COX-2 protein is partially blocked following the suppression of 
BCL-3 in siRNA treated SW837 cells. (A) Western blotting shows the expression of BCL-3 
and COX-2 proteins following IL-1β treatment (10ng/ml) in SW837 cells. The results are 
representative of three independent experiments. (B) Quantitative real-time PCR was carried 
out up to 48h post-treatment with IL-1β (10ng/ml). Data presented as a fold change of the 
untreated control. All mRNA values were normalised to the housekeeping gene TBP or HPRT 
Data represent four independent experiments, n=4. (C) Representative western blot shows the 
expression of COX-2 protein following the suppression of BCL-3 in IL-1β treated cells. 
SW837 cells were transfected with 50nM of control siRNA or BCL-3 siRNA and treated with 
IL-1β (10ng/ml) for 4h. BCL-3 and COX-2 protein levels were determined at 72h post-
transfection. Equal loading was confirmed by α-tubulin. Graph shows the fold of change of 
COX-2 protein expression following IL-1β treatment (10ng/ml) for 4h. The quantification of 
COX-2 was calculated using Image J software, to measure the change in intensity of individual 
western blot bands, and results presented normalized to the control. Results are mean values 
from three independent measurements ±SD, ***P≤0.001. (D) Data represents BCL-3 and 
COX-2 mRNA expression following transfection with BCL-3 or COX-2 siRNA (50nM). 
Quantitative real-time PCR was carried out following 2h IL-1β treatment (10ng/ml), 72h post-





values were normalised to the housekeeping gene TBP or HPRT. Data show a significant 
reduction in COX-2 mRNA on transfection with BCL-3 siRNA, even after 2h IL-1β treatment 
(10ng/ml). Transfection with COX-2 siRNA has no effect on levels of BCL-3 expression. Data 
represents four independent experiments, n=4, ANOVA was used to determine the statistical 
significance ± SEM, **P≤0.01, ***P≤0.001. 
 
 Supplementary Figure 1. Average cell yield of HCA7 cells transfected with BCL-3 or 
COX-2 siRNA. A(i) HCA7 cells were selected for preparation of conditioned medium (CM) 
due to high endogenous COX-2/PGE2 levels. In additon, unlike other colorectal cancer cells 
tested (21) the cell yield (the number of viable cells) is not significantly changed by suppression 
of BCL-3 or COX-2 over the 72h period of the experiment. Cell yield is expressed as a 
percentage of the negative siRNA control cells.  Values are the mean of three independent 
experiments ±SEM, ANOVA was used to determine the statistical significance. n=3, NS=non-
significant. (ii) Western blot confirming the knock-down of BCL-3 or COX-2 in HCA7 cells 
transfected with BCL-3 siRNA or COX-2 siRNA respectively, before harvesting the CM. 
Equal loading was confirmed by α-tubulin. The results represent three independent 
experiments. 
  
 
 
 
(24) 
 
 
 
 
(25) 
 
 
 
 
(26) 
  
 
 
 
(27) 
  
 
 
 
(28) 
  
 
 
 
(29) 
 
